CompletedPhase 3NCT00567762

Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis

Studying Vernal keratoconjunctivitis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Astellas Pharma Inc
Principal Investigator: Central Contact
Astellas Pharma Inc
Intervention: FK506(drug)
Enrollment: 56 target
Eligibility: 6 years · All sexes
Timeline: 2004 – 2004

Study locations (8)

Ehime, Japan
Hokkaido, Japan
Kagoshima, Japan
Kochi, Japan
Miyazaki, Japan
Osaka, Japan
Tochigi, Japan
Tokyo, Japan

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00567762 on ClinicalTrials.gov

Other trials for Vernal keratoconjunctivitis

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGNCT06913790
Evaluation of Central Corneal Thickness in Patients With Vernal Keratoconjunctivitis Using Topical Steroids
Superior University

See all trials for Vernal keratoconjunctivitis →

← Back to all trials